Amprologix, a spinout company from the University of Plymouth, has moved to Plymouth Science Park to become part of their growing health tech cluster and make use of cutting-edge laboratory facilities within the Derriford Research Facility.
The move to the Science Park comes as the company begins the clinical phase of its antibiotic discovery programmes.
Amprologix has pioneered a drug discovery programme focused on identifying the next generation of antibiotics, helping meet the growing need for novel approaches to the threat of antimicrobial resistance.
Professor Mat Upton, chief scientific officer of Amprologix, said:
“We are delighted to be joining the fantastic community of health tech innovators at Plymouth Science Park. The technical capabilities of the Derriford Research Facility will be vital to our continued work as we strive to combat the growing problem of antibiotic resistance.”
A UK government review in 2015 estimated that by 2050, the global cost of antibiotic resistance could rise to US$100 trillion and drug-resistant infections will cause ten million deaths a year, eclipsing the current toll from cancer and diabetes combined.
In the UK alone, the government estimates there are currently 5,000 deaths each year because antibiotics no longer work for some infections.
Amprologix was founded in 2018 to develop and commercialise the work of Professor Mat Upton of the University of Plymouth, who leads the university’s internationally recognised Antibiotic Resistant Pathogens Research Group. The company is partnered with world-leading biotechnology company Ingenza for manufacturing.
Dr Ian Fotheringham, managing director of Ingenza, said:
“This is an exciting move for Amprologix. To be part of a dynamic technology community will accelerate its growth and advance its innovative approaches to tackle the unmet global threat of antimicrobial resistance.”
Dr Fay Davies, business development manager at Plymouth Science Park, said:
“We are delighted to welcome Amprologix to Plymouth Science Park. The last year has demonstrated in the starkest possible terms the importance of innovative health tech research and capability. We look forward to supporting Amprologix as they continue their vital work developing new antibiotics and addressing the challenges of antibiotic resistance.”
To find out more about Amprologix, visit www.amprologix.com and for information on Plymouth Science Park go to www.plymouthsciencepark.com
It’s also Gathering Momentum at the Science Park – literally!
Award winning Customer Relationship Management (CRM) and Data Management consultancy, Gathering Momentum is also moving into Plymouth Science Park.
Gathering Momentum provides impartial CRM services to help their clients improve sales, employee engagement and management decision making. Through the automation of sales and marketing processes, report generation and other back office functions, Gathering Momentum enables organisations of all sizes to benefit from greater systemisation and growth.
Despite being a small team, Gathering Momentum’s experience spans 25 years, and after continued expansion of the business through 2020, the move to Plymouth Science Park will support their ambitious development plans, as they work on launching a ‘self-service’ web-based version of their CRM selection and implementation service for small to medium-sized enterprises. Founder and CEO Rob Perry said:
“Not only is the location of Plymouth Science Park ideal, but the existing tenants are in similar fields, providing us with a great opportunity to learn and grow within a supportive business environment.”
